(Total Views: 358)
Posted On: 07/05/2019 2:37:25 AM
Post# of 154928
Things become clear how important it is to treat CCR5 in various diseases. It is now essential to put the lab into function and start the 8 Phase II trial immediately.
“There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist and we are delighted to see that OB-002O has robust efficacy alone and in combination with an anti-PD-1 antibody in the CT-26 colorectal cancer model. These data support the further preclinical and clinical development of OB-002O for colorectal cancer,” said Dr. Ian McGowan, Chief Scientific Officer for Orion Biotechnology.
Mark Groper, President and CEO of Orion Biotechnology, added, “We are delighted by these preliminary data and look forward to the later stage development of OB-002O in colorectal cancer as well as exploring the efficacy of OB-002O in other cancer models.”
https://www.globenewswire.com/news-release/20...Study.html
“There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist and we are delighted to see that OB-002O has robust efficacy alone and in combination with an anti-PD-1 antibody in the CT-26 colorectal cancer model. These data support the further preclinical and clinical development of OB-002O for colorectal cancer,” said Dr. Ian McGowan, Chief Scientific Officer for Orion Biotechnology.
Mark Groper, President and CEO of Orion Biotechnology, added, “We are delighted by these preliminary data and look forward to the later stage development of OB-002O in colorectal cancer as well as exploring the efficacy of OB-002O in other cancer models.”
https://www.globenewswire.com/news-release/20...Study.html
(1)
(0)
